Literature DB >> 26280007

JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Masatoshi Kudo1, Osamu Matsui2, Namiki Izumi3, Hiroko Iijima4, Masumi Kadoya5, Yasuharu Imai6, Takuji Okusaka7, Shiro Miyayama8, Kaoru Tsuchiya3, Kazuomi Ueshima1, Atsushi Hiraoka9, Masafumi Ikeda10, Sadahisa Ogasawara11, Tatsuya Yamashita12, Tetsuya Minami13, Koichiro Yamakado14.   

Abstract

The Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma proposed by the Japan Society of Hepatology was updated in June 2014 at a consensus meeting of the Liver Cancer Study Group of Japan. Three important items have been updated: the surveillance and diagnostic algorithm, the treatment algorithm, and the definition of transarterial chemoembolization (TACE) failure/refractoriness. The most important update to the diagnostic algorithm is the inclusion of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging as a first line surveillance/diagnostic tool. Another significant update concerns removal of the term "lipiodol" from the definition of TACE failure/refractoriness.

Entities:  

Keywords:  Clinical practice guidelines; Definition of transarterial chemoembolization failure; Hepatocellular carcinoma; Japan Society of Hepatology; Liver Cancer Study Group of Japan

Year:  2014        PMID： 26280007      PMCID： PMC4531423          DOI： 10.1159/000343875

Source DB:  PubMed          Journal:  Liver Cancer        ISSN： 1664-5553            Impact factor:   11.740


  111 in total

1.  Natural course of hypovascular nodules detected on gadoxetic acid-enhanced MR imaging: presence of fat is a risk factor for hypervascularization.

Authors:  Dai Joishi; Akihisa Ueno; Akihiro Tanimoto; Shigeo Okuda; Yohei Masugi; Katsura Emoto; Kiyoshi Okuma; Michiie Sakamoto; Yutaka Imai; Sachio Kuribayashi
Journal:  Magn Reson Med Sci       Date:  2013-10-29       Impact factor: 2.471

2.  Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤ 2 cm) HCC in cirrhosis.

Authors:  Rita Golfieri; Matteo Renzulli; Vincenzo Lucidi; Beniamino Corcioni; Franco Trevisani; Luigi Bolondi
Journal:  Eur Radiol       Date:  2011-02-05       Impact factor: 5.315

3.  Using Gd-EOB-DTPA-enhanced 3-T MRI for the differentiation of infiltrative hepatocellular carcinoma and focal confluent fibrosis in liver cirrhosis.

Authors:  Yang Shin Park; Chang Hee Lee; Baek Hui Kim; Jongmee Lee; Jae Woong Choi; Kyeong Ah Kim; Jeong Hwan Ahn; Cheol Min Park
Journal:  Magn Reson Imaging       Date:  2013-05-17       Impact factor: 2.546

4.  Hypervascular hepatocellular carcinoma in the cirrhotic liver: diffusion-weighted imaging versus superparamagnetic iron oxide-enhanced MRI.

Authors:  Jin Chung; Jeong-Sik Yu; Dae Jung Kim; Jae-Joon Chung; Joo Hee Kim; Ki Whang Kim
Journal:  Magn Reson Imaging       Date:  2011-09-09       Impact factor: 2.546

5.  Detection of small hepatocellular carcinoma: intraindividual comparison of gadoxetic acid-enhanced MRI at 3.0 and 1.5 T.

Authors:  Young Kon Kim; Chong Soo Kim; Young Min Han; Hee Chul Yu; Dongil Choi
Journal:  Invest Radiol       Date:  2011-06       Impact factor: 6.016

6.  Role of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in the management of hepatocellular carcinoma: consensus at the Symposium of the 48th Annual Meeting of the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Michiie Sakamoto; Azusa Kitao; Tonsok Kim; Shun-ichi Ariizumi; Tomoaki Ichikawa; Satoshi Kobayashi; Yasuharu Imai; Namiki Izumi; Yasunari Fujinaga; Shigeki Arii
Journal:  Oncology       Date:  2013-02-20       Impact factor: 2.935

7.  Newly developed hypervascular hepatocellular carcinoma during follow-up periods in patients with chronic liver disease: observation in serial gadoxetic acid-enhanced MRI.

Authors:  Akira Yamamoto; Katsuyoshi Ito; Tsutomu Tamada; Atsushi Higaki; Akihiko Kanki; Tomohiro Sato; Daigo Tanimoto
Journal:  AJR Am J Roentgenol       Date:  2013-06       Impact factor: 3.959

8.  Presence of a hypovascular hepatic nodule showing hypointensity on hepatocyte-phase image is a risk factor for hypervascular hepatocellular carcinoma.

Authors:  Shintaro Ichikawa; Tomoaki Ichikawa; Utaroh Motosugi; Katsuhiro Sano; Hiroyuki Morisaka; Nobuyuki Enomoto; Masanori Matsuda; Hideki Fujii; Tsutomu Araki
Journal:  J Magn Reson Imaging       Date:  2013-04-30       Impact factor: 4.813

9.  Local recurrence after chemoembolization of hepatocellular carcinoma: uptake of gadoxetic acid as a new prognostic factor.

Authors:  Hideki Ishimaru; Kazuaki Nakashima; Takayuki Sakugawa; Ayami Sakamoto; Yohjiro Matsuoka; Kazuto Ashizawa; Masataka Uetani
Journal:  AJR Am J Roentgenol       Date:  2014-04       Impact factor: 3.959

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425
View more
  182 in total

1.  Surgical and Locoregional Therapy of HCC: TACE.

Authors:  Masakatsu Tsurusaki; Takamichi Murakami
Journal:  Liver Cancer       Date:  2015-07-10       Impact factor: 11.740

2.  Locoregional Therapy for Hepatocellular Carcinoma.

Authors:  M Kudo
Journal:  Liver Cancer       Date:  2015-06-05       Impact factor: 11.740

3.  Central Hepatectomy Still Plays an Important Role in Treatment of Early-Stage Centrally Located Hepatocellular Carcinoma.

Authors:  Chun-Han Chen; Tzu-Hao Huang; Cheng-Chih Chang; Wei-Feng Li; Ting-Lung Lin; Chih-Chi Wang
Journal:  World J Surg       Date:  2017-11       Impact factor: 3.352

Review 4.  Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma.

Authors:  Di-Yang Xie; Zheng-Gang Ren; Jian Zhou; Jia Fan; Qiang Gao
Journal:  Hepatobiliary Surg Nutr       Date:  2017-12       Impact factor: 7.293

5.  Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe.

Authors: 
Journal:  Liver Cancer       Date:  2015-03       Impact factor: 11.740

6.  Value of dynamic contrast enhanced MRI in predicting outcomes of HCC receiving radiotherapy.

Authors:  Masatoshi Kudo
Journal:  Hepatol Int       Date:  2015-03-07       Impact factor: 6.047

7.  Albumin-Bilirubin Grade and Hepatocellular Carcinoma Treatment Algorithm.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2017-03-09       Impact factor: 11.740

Review 8.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

9.  An efficient model for auxiliary diagnosis of hepatocellular carcinoma based on gene expression programming.

Authors:  Li Zhang; Jiasheng Chen; Chunming Gao; Chuanmiao Liu; Kuihua Xu
Journal:  Med Biol Eng Comput       Date:  2018-03-16       Impact factor: 2.602

10.  Application of propofol combined with sevoflurane anesthesia in staged hepatectomy liver detachment and portal vein ligation.

Authors:  Fei Xu; Hongbo Jiang; Meishan Jin; Qihua Peng
Journal:  Exp Ther Med       Date:  2021-06-30       Impact factor: 2.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.